76 results about "Motor disorder" patented technology

The invention relates to the technical field of pressure sore nursing, discloses an intelligent nursing system for pressure sore nursing of a patient suffering from cerebral infarction and a back raising optimization method, and is particularly used for solving the problem that the risk of pressure sore deterioration is caused due to the fact that the patient suffering from cerebral infarction cannot sense local pressure and abnormal shearing force in the back raising process in time due to feeling and dyskinesia. The system comprises a data acquisition module, a feature extraction module, a feature fusion module, a feature dimension reduction module, a pressure sore risk prediction module, a feedback control module and a back-up execution module, and the method is based on a target function, and dynamically adjusts back-up execution parameters in combination with acquired data and pressure sore risk scores and grades obtained through analysis. According to the method, multi-modal data are collected in real time, the body posture, motion trail, local stress, shearing force and pressure of the patient in the back raising process are comprehensively considered, closed-loop control is optimized through an objective function, the back raising speed, angle and supporting force are dynamically adjusted, and pressure sore aggravation or secondary injury of the patient after cerebral infarction in the back raising process is prevented.

Provided herein are optionally substituted pyrazolylacetamides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating diseases or disorders, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania, tinnitus, neurodevelopmental diseases or disorders, a smooth muscle contractility disorder, Dravet syndrome, posttraumatic stress disorder (PTSD), with such compounds and pharmaceutical compositions.

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I):and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

Provided herein are optionally substituted pyrazolylacetamides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating diseases or disorders, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania, tinnitus, neurodevelopmental diseases or disorders, a smooth muscle contractility disorder, Dravet syndrome, posttraumatic stress disorder (PTSD), with such compounds and pharmaceutical compositions.

Alkoxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, and Attention Deficit Hyperactivity Disorder (ADHD), choreiform movements, speech delay, learning disabilities, depression, hyperkinetic movement disorders characterised by chorea and / or dystonia, psychosis, cognitive deficits in schizophrenia, affective disorders, bipolar disorder, Alzheimer's disease and basal ganglia disorders.

The invention discloses an application of rapamycin in preparation of a composition for treating a hereditary spastic paraplegia SPG subtype. The rapamycin can obviously improve the motion disorder and pathological injury phenotype of an SPG80 subtype mammal model, improve the lysosome function and promote the autophagy process through mTOR inhibition, provides specific intervention for nerve cell apoptosis and a glial cell abnormal activation mechanism caused by UBAP1 deletion, fills the blank that no effective treatment means exists for the SPG subtype, and has a good application prospect. A theoretical basis is provided for clinical treatment of patients, and a reference is provided for other SPG variations (such as SPG3A).

This invention belongs to the field of animal model technology, specifically disclosing a method for constructing a primary ciliary motor disorder hydrocephalus model, comprising the following steps: screening benzimidazole as a modeling agent; administering benzimidazole solution to experimental animals and setting up a blank control group; conducting experimental verification through pathological morphology and behavioral methods; if the experimental animals show significant ventricular enlargement and significant decrease in motor ability, the primary ciliary motor disorder hydrocephalus model is successfully constructed. This invention employs the above-mentioned novel method for constructing a primary ciliary motor disorder hydrocephalus model. The constructed hydrocephalus model exhibits good stability and repeatability, is objective and simple, and is highly operable, reducing other possible interfering factors. It provides a necessary experimental foundation for studying the mechanism of primary ciliary motor disorder hydrocephalus and developing treatment methods.

A compound of Formula I or II or a salt thereof; Wherein R1 and R3 are as herein defined; R3 is selected from C1-6 alkyl, C1-6 fluoroalkyl, Cl, F, I, Br, CN, hydrogen, and C1-6 alkyoxy; R4 is selected

Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipoloar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.

The present disclosure provides for a helmet system for use in MEG scans of a pediatric subject, such as a human subject, and methods of making the helmet system. MEG is a noninvasive imaging technique for capturing brain activity by measuring small magnetic fields produced in the brain, where the helmet system can be used for MEG scans to detect, for example, sleep disturbances, seizures, and motor disorders.

The invention discloses a substituted aromatic heterocyclic compound containing a spiro skeleton as well as a preparation method and application thereof, and relates to the field of medicinal chemistry, in particular to the substituted aromatic heterocyclic compound containing the spiro skeleton or pharmaceutically acceptable salt of the substituted aromatic heterocyclic compound, a necessary composition containing the compounds and medical application of the substituted aromatic heterocyclic compound. The invention relates to an application of a monoacylglyceridase inhibitor, in particular to application of the monoacylglyceridase inhibitor as a monoacylglyceridase (MAGL) inhibitor in preparation of drugs for preventing and / or treating MAGL-related diseases. Comprise depression, schizophrenia, bi-directional disorder, dyskinesia, traumatic brain injury, neuroinflammation, Parkinson's disease, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, anxiety disorder, pain, metabolic disorder, alcoholic fatty liver disease, non-alcoholic fatty liver disease, hepatic fibrosis, cholestasis, nephropathy and other related diseases.

The invention relates to a method for reducing the occurrence of kinetosis-related disturbances in a passenger while driving a vehicle (1). During driving of the vehicle (1), dynamic-dependent vibrations caused by the vehicle's operation are acoustically and / or haptically imitated depending on detected current or predicted driving dynamics. According to the invention, the acoustic and / or haptic imitation of the vibrations is carried out depending on passenger-related preferences, with the output of acoustic and / or haptic vibrations being synchronized with respect to driving dynamics influences.

This invention relates to the treatment of glucose transporter type 1 deficiency syndrome (Glut1-DS). In particular, the invention relates to specific medium-chain triglyceride compositions, enriched for C10 (decanoic acid), for use in treating movement disorders in Glut1-DS patients.

Combination compositions of Compound 1 and fesoterodine for use in the treatment of neurological disorders, such as schizophrenia, Alzheimer's disease psychosis, Parkinson's disease psychosis, cognitive in Alzheimer's disease, psychosis in Lewy body dementia, bipolar disorder, and dyskinesia, are described.

The present disclosure relates, inter alia, to certain compounds, compositions, and pharmaceutical compositions thereof that modulate the activity of transporter vesicular monoamine transporter 2 (VMAT2), and to methods for treating transporter vesicular monoamine transporter 2 mediated disorders, such as neurological or psychiatric diseases or disorders, including but not limited to hyperdyskinesia (e.g., hyperdyskinesia). Delayed dyskinesia, Tourette's Syndrome, Huntington's Disease, twitch, ataxia, chorea (such as chorea associated with Huntington's Disease), muscular dystonia, lateral spasm, muscular spasm, restless leg Syndrome, and tremor). The present disclosure also relates to synthetic processes and intermediates useful for preparing the compounds.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI). vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

This invention pertains to the prevention and treatment of aging-associated disease. The invention relates to the use of benzodioxane inhibitors of leukotriene production through modulation of leukotriene A4 hydrolase (“LTA4H”) to treat and / or prevent conditions associated with aging such as cognitive disorders, motor disorders, and neuroinflammation.

Disclosed are compounds of Formula I that are useful as Monoacylglycerol lipase (MAGL) inhibitorsThese compounds may be used in pharmaceutical compositions, formulations, and methods for the treatment of disease states, disorders, and conditions benefited by the inhibition or modulation of MAGL activity, such as, but are not limited to, anxiety and mood disorder, metabolic disorder, a neurodegenerative disorder, mental disorder, brain disorder, pain, inflammatory disorder, cancer, Alzheimer's disease, movement disorders, epilepsy or stroke.

The invention belongs to the field of medicinal chemistry, and discloses a 3-(2, 4-dihydroxyphenyl)-2H-chromene-2-ketone derivative and application thereof. According to the present invention, 3-(2, 4-dihydroxyphenyl)-2H-chromene-2-ketone is adopted as a lead compound to carry out corresponding structure optimization so as to obtain a series of 3-(2, 4-dihydroxyphenyl)-2H-chromene-2-ketone PDE2 inhibitor derivatives, and the general formula of the 3-(2, 4-dihydroxyphenyl)-2H-chromene-2-ketone PDE2 inhibitor derivatives is shown in the specification. The compounds show excellent inhibitory activity on PDE2, have significant application prospects for treating central nervous system diseases, have potential curative effects on improving memory deficit, improving learning and cognition functions, relieving dyskinesia and the like, can be used as key active ingredients, are used for researching and developing special pharmaceutical preparations for inhibiting PDE2 activity, and have broad application prospects. And a new way is expected to be opened up for the treatment of central nervous system diseases.

The invention discloses a 3-phenylcoumarin derivative as well as a preparation method and application thereof. The 3-phenylcoumarin derivative is obtained by carrying out structure optimization by taking 3-phenylcoumarin as a lead compound. A biological activity test result shows that the synthesized 3-phenylcoumarin derivative has good PDE2 inhibitory activity, the IC50 value of part of compounds is less than 1 mu M, and the 3-phenylcoumarin derivative has the potential of treating central nervous system diseases such as memory deficit, low learning and cognition functions and dyskinesia and can be used as an active component for preparing the medicine for inhibiting the PDE2 activity.

This invention relates to the field of natural language processing technology, specifically to a triage method and system for neurological diseases, comprising the following steps: segmenting the syntactic structure of the patient's chief complaint text sequence and identifying nodes; calculating and quantifying the nesting degree of the patient's linguistic organization logic; and obtaining a syntactic potential depth value. This invention can filter out noise interference from complex clinical expressions and extract neurological syndrome features by comparing them with a preset internal capsule lesion pattern. By jointly analyzing feature tensors pointing to limb paralysis with syntactic potential depth values ​​below the normal threshold, dual cross-validation of somatic motor disorders and central cognitive impairment is achieved. Furthermore, by comparing with feature thresholds of peripheral nerve or spinal cord lesions, the specificity of identifying central acute and severe illnesses such as ischemic stroke is improved, optimizing the accuracy of emergency triage.

In one embodiment of the present invention, the present invention relates to a pharmaceutical composition for treating an individual having a disorder selected from communication disorders, motor impairments, cognitive impairments, mental disorders, sensory disorders, autism spectrum disorders, and pervasive developmental disorders, the pharmaceutical composition comprising L-serine or a pharmaceutically acceptable salt thereof.

The present invention provides methods for screening for nucleotide sequences encoding the capsid of adeno-associated virus ("AAV") particles capable of infecting neurons or subcompartments thereof in a subject, including neurons derived from induced pluripotent stem cells or embryonic stem cells. The present invention also provides AAV capsids, nucleotide sequences encoding the capsids, expression vectors, viral particles, cells, and kits for use in methods for treating neuromuscular or neuromotor disorders (e.g., spasticity). Sequences generated by these methods may lead to new gene therapies that offer high specificity that can be personalized to the subject because they are targeted to select neuronal populations, such as motor neurons that innervate muscle cells.

In various embodiments methods and devices are provided for facilitating sexual function in a subject with a neuromotor disorder. In certain embodiments the methods involve providing magnetic stimulation of the spinal cord at a location, frequency and intensity sufficient to facilitate sexual function.

To provide 19-nor C3,3-disubstituted C21-N-pyrazolyl steroids, and methods for use thereof.SOLUTION: Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I), and pharmaceutically acceptable salts thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.SELECTED DRAWING: None

The invention discloses a composition which is composed of notoginsenoside Rg1 and gastrodin, the composition is applied to preparation of drugs for treating neurodegenerative diseases, and experimental results show that the composition can significantly improve MPTP-induced zebrafish dyskinesia and brain tissue structure damage, shows a synergistic neuroprotective effect, and can be used for treating neurodegenerative diseases. The composition provided by the invention provides a new effective means for treatment of neurodegenerative diseases, and has important clinical application value and wide development prospect.

This invention relates to the treatment of glucose transporter type 1 deficiency syndrome (Glut1-DS). In particular, the invention relates to specific medium-chain triglyceride compositions, enriched for C10 (decanoic acid), for use in treating movement disorders in Glut1-DS patients.

Provided is use of typhaneoside in preparing a medicament for treating ischemic stroke. Experiments have proved that typhaneoside can reduce the cerebral infarction volume, increase the cerebral blood perfusion volume, improve nerve functions and ameliorate motor disorders, reduce ROS levels, and protect neurons, thereby effectively treating ischemic stroke.

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I): and pharmaceutically acceptable salts thereof, wherein - - - - -, R1, R2, R3a, R3b, R4a , R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.